Leadership

TransCode's senior leadership team combines decades of oncology drug discovery and development expertise, life science business acumen and Wall Street knowledge to add both scientific insight and valuable strategic perspective to address cancer and create a sustainable commercialization product pipeline. Our scientists have decades of experience in the foundational areas of RNA and drug development, employing a variety of RNA approaches based on cancer indication and patient needs.

Executive Team

​Michael Dudley
Founder, President & CEO

Tom Fitzgerald, MBA
CFO, VP of Administration

Susan Duggan, RN, MBA
VP of Clinical Operations

Dustan Bonnin, CVA, MBA
VP of Corporate Strategy

Alan Freidman
​VP of Investor Relations

Zdravka Medarova, PhD
Founder/Chief Technology Officer

Peter Liu, PhD
VP R&D and ​Chief Scientist

Eric Wesoloski
​Sr. Director Quality

Subrata Ghosh, PhD
​Principal Scientist

Ram Bhat, PhD
​Sr. Director CMC

---

Board of Directors

Philippe Calais, PhD
​Board Chair

Magda Marquet, PhD
​Director

Erik Manting, PhD
​Director

Michael Dudley, President, CEO and Director

CFO, VP of Administration Director

---

Advisory Board

Anna Moore, PhD
​Founder

Keith Flaherty, MD

Raghu Kalluri, MD, PhD

George Calin, MD, PhD

Dejan Juric, MD

---

Dmitry Samarsky
​PhD

G. Susan Srivatsa
​PhD

Raul Mostoslavsky
​MD, PhD

Lubomir Nechev
​PhD

Frank J.Slack
​PhD

---

Mehmet Yigit
​PhD

Betsabeh Madani Hermann
​MBA​, MENG

Jerome Lewis
​PhD, MBA

John Henneman III
​JD

Oliver Steinbach
​PhD